Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. OTIPRIO has also completed a Phase III clinical trial for treating swimmer's ear and a Phase II clinical trial for treating acute otitis media with tubes. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
http://www.priceseries.com/trade/OTIC-Otonomy-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2020120920201230.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments